The Cost-Effectiveness of Ustekinumab in Moderate to Severely Active Crohn’s Disease in Sweden

OBJECTIVES: Human monoclonal antibody ustekinumab is a novel Crohn's disease (CD) treatment option which blocks pro-inflammatory cytokines interleukins (IL)-12 and IL-23.The aim was to assess the cost-effectiveness of ustekinumab in moderate to severely active CD in Sweden. METHODS: A cost-effe...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Value in health 2017-10, Vol.20 (9), p.A634
Hauptverfasser:	Hansson-Hedblom, A, Almond, C, Borgström, F, Sly, I, Enkusson, D, Troelsgaard Buchholt, A, Karlsson, L
Format:	Artikel
Sprache:	eng
Schlagworte:	Clinical research Clinical trials Cost analysis Crohn's disease Discontinued Efficacy Experts Health care expenditures Immunoglobulins Immunotherapy Indirect costs Induction Inflammation Inflammatory bowel diseases Interleukin 23 Medical treatment Meta-analysis Monoclonal antibodies Quality adjusted life years Remission Remission (Medicine) Robustness Sensitivity analysis Surgery Tumor necrosis factor-α Willingness to pay
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!